Last reviewed · How we verify
Comparator: paroxetine HCL — Competitive Intelligence Brief
phase 3
Selective serotonin reuptake inhibitor (SSRI)
Serotonin transporter (SERT)
Psychiatry / Neurology
Small molecule
Live · refreshed every 30 min
Target snapshot
Comparator: paroxetine HCL (Comparator: paroxetine HCL) — Merck Sharp & Dohme LLC. Paroxetine HCl selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Comparator: paroxetine HCL TARGET | Comparator: paroxetine HCL | Merck Sharp & Dohme LLC | phase 3 | Selective serotonin reuptake inhibitor (SSRI) | Serotonin transporter (SERT) | |
| Lexapro | escitalopram | Generic (originally Lundbeck/Forest) | marketed | Selective Serotonin Reuptake Inhibitor (SSRI) | Serotonin (5-HT) reuptake transporter | 2002-08-14 |
| Prozac | fluoxetine | Eli Lilly and Company | marketed | Selective Serotonin Reuptake Inhibitor (SSRI) | Serotonin reuptake transporter | 1987-12-29 |
| SSRI antidepressants | SSRI antidepressants | Nanjing Medical University | marketed | Selective serotonin reuptake inhibitor (SSRI) | Serotonin transporter (SERT) | |
| SSRI (SEROPLEX ou ZOLOFT) | SSRI (SEROPLEX ou ZOLOFT) | Centre Hospitalier Universitaire Dijon | marketed | Selective serotonin reuptake inhibitor (SSRI) | Serotonin transporter (SERT) | |
| Zoloft tablets | Zoloft tablets | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | marketed | Selective serotonin reuptake inhibitor (SSRI) | Serotonin transporter (SERT) | |
| sertraline fluvoxamine | sertraline fluvoxamine | Second Affiliated Hospital, School of Medicine, Zhejiang University | marketed | Selective serotonin reuptake inhibitor (SSRI) | Serotonin transporter (SERT) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Selective serotonin reuptake inhibitor (SSRI) class)
- University of Texas Southwestern Medical Center · 3 drugs in this class
- Johns Hopkins University · 2 drugs in this class
- GlaxoSmithKline · 2 drugs in this class
- Daiichi Sankyo Co., Ltd. · 1 drug in this class
- Guangdong Provincial People's Hospital · 1 drug in this class
- Janssen Research & Development, LLC · 1 drug in this class
- Medical University of Vienna · 1 drug in this class
- Massachusetts General Hospital · 1 drug in this class
- Fundació Sant Joan de Déu · 1 drug in this class
- Centre Hospitalier Universitaire Dijon · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Comparator: paroxetine HCL CI watch — RSS
- Comparator: paroxetine HCL CI watch — Atom
- Comparator: paroxetine HCL CI watch — JSON
- Comparator: paroxetine HCL alone — RSS
- Whole Selective serotonin reuptake inhibitor (SSRI) class — RSS
Cite this brief
Drug Landscape (2026). Comparator: paroxetine HCL — Competitive Intelligence Brief. https://druglandscape.com/ci/comparator-paroxetine-hcl. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab